Purpura
MONDO:0002610A small blood vessel hemorrhage into the skin and/or mucous membranes. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.
Also known as: purpura, purpura (disease)
149 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for low platelets: avatrombopag tested in japanese ITP patients
Disease control CompletedThis study tested a drug called avatrombopag in 19 Japanese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal was to see if the drug could safely increase platelet counts over 26 weeks. Parti…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could help adults with low platelet disorder
Disease control CompletedThis Phase 3 trial tested an oral drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants who had not responded well to prior treatments received eith…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedThis study tested a new medicine called HBM9161, given as a weekly shot under the skin, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising the risk of bleeding. The trial included 36 people who had not responded…
Phase: PHASE2, PHASE3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
Disease control CompletedThis study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Acid lock could fight blood infections in cancer patients
Disease control CompletedThis study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug shows promise for Long-Term platelet control in rare bleeding disorder
Disease control CompletedThis phase 3 trial tested the long-term safety and effectiveness of efgartigimod, an IV drug, in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants received efgartigimod infusions over 52 w…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for bleeding risk in hepatitis b patients?
Disease control CompletedThis study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Low-Dose rituximab shows promise for blood disorder
Disease control CompletedThis study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition causing low platelet counts and bleeding. The goal was to see which regimen better raises platelets and controls bleeding. Participants had failed or relapsed on stand…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Breakthrough drug combo may replace plasma exchange for rare blood disease
Disease control CompletedThis study tested whether a drug called caplacizumab, combined with immune-suppressing medicines, could treat a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual plasma exchange procedure. Fifty-one adults aged 18 to …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for ITP patients: drug boosts platelet counts in early study
Disease control CompletedThis study tested a drug called lusutrombopag in 17 Chinese adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants had failed standard treatments and took the drug for up to 12 w…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New blood product could cut transfusions in major surgeries
Disease control CompletedThis study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for oth…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug shows promise in preventing deadly blood clot relapses in japanese patients
Disease control CompletedThis study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goa…
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental antibody shows promise for rare amyloid disease
Disease control CompletedThis phase II trial tested the drug isatuximab in 43 patients with AL amyloidosis that had come back or stopped responding to treatment. Isatuximab is a monoclonal antibody that may help stop abnormal protein buildup. The study measured how well the drug reduced disease markers a…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
New combo therapy shows promise for Steroid-Resistant ITP
Disease control CompletedThis completed phase 3 trial tested whether adding all-trans retinoic acid (ATRA) to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that did not respond to steroids. The study enrolled 96 participants and measured sustained platelet …
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:57 UTC
-
Stomach bug treatment may boost blood platelets in ITP patients
Disease control CompletedThis study looked at whether treating Helicobacter pylori (a common stomach infection) with antibiotics can raise platelet counts in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. Researchers enrol…
Phase: NA • Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Monthly chat group may ease isolation for young transplant patients
Symptom relief CompletedThis study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Asthma drug may ease cancer treatment side effects
Symptom relief CompletedThis study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who will get chronic ITP?
Knowledge-focused CompletedThis completed study looked at blood samples from 70 children and adults newly diagnosed with immune thrombocytopenic purpura (ITP), a condition that causes easy bruising and bleeding. Researchers wanted to see if certain immune and blood markers could predict whether the disease…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New tests could help spot hidden blood disorder in seniors
Knowledge-focused CompletedThis study followed 37 adults over age 60 with unexplained low platelet counts to see if certain tests could predict immune thrombocytopenic purpura (ITP). Participants had blood tests, bone marrow biopsies, and a short course of the steroid prednisone. The goal was to find which…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Could cancer trick the body into attacking its own platelets?
Knowledge-focused CompletedThis study looked at 33 adults who had both immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — and cancer. Researchers wanted to see if treating the cancer could also improve ITP. They also investigated whether cancer cells might mimic platel…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
ITP study reveals hidden toll on brain and body
Knowledge-focused CompletedThis study looked at how chronic immune thrombocytopenia (ITP) affects thinking skills and fatigue in adults. Researchers measured brain function and inflammation using blood tests and questionnaires in 97 patients. The goal was to better understand these connections, not to test…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
AI and MRI join forces to speed up cancer radiation planning
Knowledge-focused CompletedThis completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…
Phase: NA • Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Tiny study asks: does aspirin work in patients with low platelets?
Knowledge-focused CompletedThis study looked at how well a daily low-dose aspirin works in people who have both immune thrombocytopenia (low platelets) and heart disease. Only 4 adults took part. Researchers measured platelet function after aspirin to see if the standard dose is enough to prevent blood clo…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Massive study reveals hidden struggles of stem cell survivors
Knowledge-focused CompletedThis study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Lung scans reveal hidden patterns in blood disease patients
Knowledge-focused CompletedThis completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…
Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Study reveals tricky platelet swings in blood disorder drug response
Knowledge-focused CompletedThis study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessar…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:26 UTC